Anastasia Susie Mihailidou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anastasia Susie Mihailidou has a total of 211 co-authors. Here are the top co-authors by number of shared publications:
Mahidi Mardini
7 shared publications- Helge H. Rasmussen
University of Sydney
6 shared publications - Michael P. Jones
School of Psychological Sciences, Macquarie University, North Ryde, Australia
6 shared publications Anthony W. Ashton
Perinatal Research Laboratory, Kolling Institute, Sydney, NSW, Australia; Division of Perinatal Research, Royal North Shore Hospital, Sydney, NSW, Australia
4 shared publications- Marie-Christine Morel-Kopp
Royal North Shore Hospital
4 shared publications Christopher Ward
3 shared publications
Latest Publications
- Open Access
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Population‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018)
Background: In August 2025, the American Heart Association and American College of Cardiology released updated hypertension guidelines. Under the new guidelines, therapy is advised at blood pressure ≥130/80 mm Hg in adults with diabetes, chronic kidney disease, or a Predicting Risk of Cardiovascular Disease Events‐estimated 10‐year cardiovascular disease risk ≥7.5%. The long‐term population‐level changes following these guidelines remains uncertain. Methods: We analyzed NHANES (National Health and Nutrition Examination Survey) 2009 to 2018 data linked to mortality through 2019. Hypertensive adults without baseline cardiovascular disease were included. Treatment eligibility was defined using guideline criteria. Cox models estimated associations between antihypertensive therapy and all‐cause and cardiovascular mortality. Simulation analyses projected lives saved under full and partial treatment uptake. Results: The weighted cohort represented 81.0 million US adults with hypertension. Of these, 22.8 million (28%) were guideline eligible for therapy; 13.1 million (57%) were treated, and 9.7 million (43%) remained untreated. Antihypertensive therapy was associated with a 23% reduction in all‐cause mortality (hazard ratio [HR], 0.77 [95% CI, 0.63–0.94]) and 50% reduction in cardiovascular mortality (HR, 0.50 [95% CI, 0.36–0.68]). At 10 years, universal treatment of eligible but untreated adults was projected to prevent ~200 900 all‐cause and ~ 162 600 cardiovascular deaths. Benefits were greatest in adults with diabetes. Conclusions: In this nationally representative cohort, nearly 1 in 3 US adults with hypertension were newly eligible for therapy under the guideline, yet >2 in 5 remained untreated. Extending treatment to all eligible adults could prevent >200 000 all‐cause and 160 000 cardiovascular deaths over the next decade.
- 4 August 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (15)
Open AccessPopulation‐Level 10‐Year Implications of the New 2025 American Heart Association/American College of Cardiology Hypertension Guideline Recommendations for Primary Prevention in the United States: A NHANES‐Based Cohort Study (2009–2018)
Background: In August 2025, the American Heart Association and American College of Cardiology released updated hypertension guidelines. Under the new guidelines, therapy is advised at blood pressure ≥130/80 mm Hg in adults with diabetes, chronic kidney disease, or a Predicting Risk of Cardiovascular Disease Events‐estimated 10‐year cardiovascular disease risk ≥7.5%. The long‐term population‐level changes following these guidelines remains uncertain. Methods: We analyzed NHANES (National Health and Nutrition Examination Survey) 2009 to 2018 data linked to mortality through 2019. Hypertensive adults without baseline cardiovascular disease were included. Treatment eligibility was defined using guideline criteria. Cox models estimated associations between antihypertensive therapy and all‐cause and cardiovascular mortality. Simulation analyses projected lives saved under full and partial treatment uptake. Results: The weighted cohort represented 81.0 million US adults with hypertension. Of these, 22.8 million (28%) were guideline eligible for therapy; 13.1 million (57%) were treated, and 9.7 million (43%) remained untreated. Antihypertensive therapy was associated with a 23% reduction in all‐cause mortality (hazard ratio [HR], 0.77 [95% CI, 0.63–0.94]) and 50% reduction in cardiovascular mortality (HR, 0.50 [95% CI, 0.36–0.68]). At 10 years, universal treatment of eligible but untreated adults was projected to prevent ~200 900 all‐cause and ~ 162 600 cardiovascular deaths. Benefits were greatest in adults with diabetes. Conclusions: In this nationally representative cohort, nearly 1 in 3 US adults with hypertension were newly eligible for therapy under the guideline, yet >2 in 5 remained untreated. Extending treatment to all eligible adults could prevent >200 000 all‐cause and 160 000 cardiovascular deaths over the next decade.
- Open Access
- 7 April 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (2) , 50-54
Measuring blood pressure accurately
Accurately measuring blood pressure is imperative for the diagnosis and management of hypertension. This article summarises different methods and devices for measuring blood pressure, and factors that influence measurement accuracy.
- 7 April 2026
- Published by Therapeutic Guidelines Limited in Australian Prescriber
- Vol. 49 (2) , 50-54
Open AccessMeasuring blood pressure accurately
Accurately measuring blood pressure is imperative for the diagnosis and management of hypertension. This article summarises different methods and devices for measuring blood pressure, and factors that influence measurement accuracy.
- 21 January 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (13) , 2343-2344
Post-partum: the window for implementing prevention into clinical practice
- 21 January 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (13) , 2343-2344
Post-partum: the window for implementing prevention into clinical practice
- 2 January 2026
- Published by Taylor & Francis in Contemporary Nurse
- Vol. 62 (1) , 16-17
Digital transformation of cardiovascular care – are we ready?
- 2 January 2026
- Published by Taylor & Francis in Contemporary Nurse
- Vol. 62 (1) , 16-17
Digital transformation of cardiovascular care – are we ready?
- Open Access
- 20 November 2025
- Published by Springer Nature in Hypertension Research
- Vol. 49 (3) , 904-915
Sex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervation
Our aim was a sex-specific analysis to characterize the phenotype for women with resistant hypertension (rHTN), an understudied population, referred for renal denervation (RDN) from the Global SYMPLICITY Registry DEFINE ( N = 3332 patients). For this analysis, 2502 patients with uncontrolled hypertension (office systolic blood pressure (SBP) ≥140 mmHg, ≥3 antihypertensive drugs) were referred for RDN. Age at baseline was 18–88 years for men and 21–89 years for women. We used propensity score matching to account for demographic differences at baseline identified by multivariate regression analysis. Changes in BP, outcomes (all-cause death, cardiac death, stroke, myocardial infarction), and quality of life (QoL) after 36 months were assessed. Women had fewer comorbidities at baseline but had higher BP and worse QoL, anxiety, and depression compared to men. After propensity matching to minimize bias, BP changes were comparable by sex, and BP was significantly reduced from baseline following RDN. Women ≥55 years of age with resistant hypertension had a greater reduction in BP compared with women 178 mmHg), cardiac death was more prevalent in women (6.1%) than men (1.7%). Our sex-stratified analysis of the global registry allowed a longitudinal assessment, providing important insights into the phenotype of resistant hypertension in women. We identified sex-specific differences that highlight the need for early detection and management of hypertension in women.
- 20 November 2025
- Published by Springer Nature in Hypertension Research
- Vol. 49 (3) , 904-915
Open AccessSex stratified analysis of patients with resistant hypertension from the Global SYMPLICITY Registry of renal denervation
Our aim was a sex-specific analysis to characterize the phenotype for women with resistant hypertension (rHTN), an understudied population, referred for renal denervation (RDN) from the Global SYMPLICITY Registry DEFINE ( N = 3332 patients). For this analysis, 2502 patients with uncontrolled hypertension (office systolic blood pressure (SBP) ≥140 mmHg, ≥3 antihypertensive drugs) were referred for RDN. Age at baseline was 18–88 years for men and 21–89 years for women. We used propensity score matching to account for demographic differences at baseline identified by multivariate regression analysis. Changes in BP, outcomes (all-cause death, cardiac death, stroke, myocardial infarction), and quality of life (QoL) after 36 months were assessed. Women had fewer comorbidities at baseline but had higher BP and worse QoL, anxiety, and depression compared to men. After propensity matching to minimize bias, BP changes were comparable by sex, and BP was significantly reduced from baseline following RDN. Women ≥55 years of age with resistant hypertension had a greater reduction in BP compared with women 178 mmHg), cardiac death was more prevalent in women (6.1%) than men (1.7%). Our sex-stratified analysis of the global registry allowed a longitudinal assessment, providing important insights into the phenotype of resistant hypertension in women. We identified sex-specific differences that highlight the need for early detection and management of hypertension in women.
- Open Access
- 20 February 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 52, 100510
Impact of climate change and the environment on cardiovascular health and role of healthcare
- 20 February 2025
- Published by Elsevier in American Heart Journal Plus: Cardiology Research and Practice
- Vol. 52, 100510
Open AccessImpact of climate change and the environment on cardiovascular health and role of healthcare
- Open Access
- 14 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2463435
Home blood pressure during night-time sleep – a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled trial
This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.
- 14 February 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2463435
Open AccessHome blood pressure during night-time sleep – a feasible treatment target for patients with hypertension: a proof-of-concept randomised controlled trial
This trial assessed the feasibility of titrating evening dosing of anti-hypertensive medications based on nighttime home blood pressure measurement (HBPM) readings in primary care for hypertensive (HT) patients. 78 patients with nocturnal HT and stage I daytime HT were randomly assigned in a 1:1 ratio to either nighttime HBPM measurements (intervention group) or daytime HBPM measurements (control group). Nighttime blood pressure (BP) was measured 3x per night for at least two nights over 1 week using an automatic and validated HBPM device. The intervention group and control group aimed to achieve systolic BP <120 mmHg on nocturnal HBPM and systolic BP <135 mmHg on daytime HBPM respectively. All patients were seen every four weeks and followed the same drug titration algorithm. The trial achieved a recruitment rate of 6.5 persons per month and a retention rate of 96.1%. In the intervention group, patients provided ≥6 (considered adequate) and ≥9 nighttime HBPM readings for 77.5% and 63.8% of their follow-ups, respectively. At 6-month, both groups had similar nighttime, 24-hour, and daytime BP on ambulatory BP monitoring, as well as similar numbers of non-dippers and healthcare utilisation. Most patients reported that they learned more from their HBPM nighttime readings and found the intervention well-tolerated. Adjusting evening dosage of anti-HT medications based on nighttime HBPM is a potential and feasible treatment approach for patients with nocturnal HT in primary care. This approach is well-accepted by patients and results in at least non-inferior BP control. Although titrating medications according to nighttime HBPM readings may improve nighttime BP, the small sample size limited statistical significance and the single-centre design restricted generalizability. Additionally, a few patients exhibited fair adherence to nighttime HBPM. Further randomised controlled trials are required to confirm that targeting nocturnal BP should be the primary treatment goal for HT.
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , e71-e73
Improving #Hypertension Awareness: Utility of Social Media to Communicate About High Blood Pressure
- 1 June 2024
- Published by Wolters Kluwer Health in Hypertension
- Vol. 81 (6) , e71-e73
Improving #Hypertension Awareness: Utility of Social Media to Communicate About High Blood Pressure
- 1 July 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (7) , 1417-1426
Sex Differences in Ambulatory Blood Pressure Levels and Subtypes in a Large Italian Community Cohort
Background: Sex differences in blood pressure control are recognized. We systematically investigated sex differences in specific components of ambulatory blood pressure (ABP), including variability, day-night changes, morning surge, and hypertension types. Methods: We analyzed ABPs of 52 911 participants (45.6% male, 54.4% female, 37.0% treated for hypertension) visiting 860 Italian community pharmacies. Sex differences in ABP levels and patterns were evaluated in the whole group and 4 risk groups (antihypertensive-treated patients, patients with diabetes, dyslipidemia, or cardiovascular disease). Results: Average 24-hour, day-time, and night-time blood pressure values were consistently higher in males than females ( P P P P P P <0.001). Sex differences in ABP levels and patterns detected in the whole population were replicated in all risk groups, except for the prevalence of abnormal morning surge (between sexes difference in antihypertensive-treated participants only). Conclusions: Females show better ABP control than males, but with an increased blood pressure variability and a greater prevalence of white-coat hypertension. These findings support tailored management of hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03781401
- 1 July 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (7) , 1417-1426
Sex Differences in Ambulatory Blood Pressure Levels and Subtypes in a Large Italian Community Cohort
Background: Sex differences in blood pressure control are recognized. We systematically investigated sex differences in specific components of ambulatory blood pressure (ABP), including variability, day-night changes, morning surge, and hypertension types. Methods: We analyzed ABPs of 52 911 participants (45.6% male, 54.4% female, 37.0% treated for hypertension) visiting 860 Italian community pharmacies. Sex differences in ABP levels and patterns were evaluated in the whole group and 4 risk groups (antihypertensive-treated patients, patients with diabetes, dyslipidemia, or cardiovascular disease). Results: Average 24-hour, day-time, and night-time blood pressure values were consistently higher in males than females ( P P P P P P <0.001). Sex differences in ABP levels and patterns detected in the whole population were replicated in all risk groups, except for the prevalence of abnormal morning surge (between sexes difference in antihypertensive-treated participants only). Conclusions: Females show better ABP control than males, but with an increased blood pressure variability and a greater prevalence of white-coat hypertension. These findings support tailored management of hypertension. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03781401